Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy - Top-Institutions - MDSpire

Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy

  • By

  • Sophia Kennedy

  • Jerin Thomas

  • Stella D’Arcy

  • Ivie Odia

  • Dev Kamdar

  • Lucio Pereira

  • Danielle Scarola

  • Brett Miles

  • Douglas Frank

  • Charit Taneja

  • Nagashree Seetharamu

  • Rajarsi Mandal

  • May 28, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The Cancer Genome Atlas (TCGA)
    The Cancer Genome Atlas (TCGA)

    Bethesda, MD

    Key Differentiators

    • Oncology
    • Genomics

  • #2

    Northwell Health
    Northwell Health

    New Hyde Park, NY

    Key Differentiators

    • Healthcare
    • Research

  • #3

    Virginia Commonwealth University
    Virginia Commonwealth University

    Richmond, VA

    Key Differentiators

    • Healthcare
    • Research

Original Source(s)

Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy

  • by Sophia Kennedy, Jerin Thomas, Stella D’Arcy, Ivie Odia, Dev Kamdar, Lucio Pereira, Danielle Scarola, Brett Miles, Douglas Frank, Charit Taneja, Nagashree Seetharamu, Rajarsi Mandal

  • May 28, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?